| Rituximab therapy in nephrotic syndrome due to AH amyloidosis. | |
| | |
MedLine Citation:
|
PMID: 19590993 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We report a patient with AH amyloidosis associated with lymphoplasmacytic leukemia that has remained in a stable state with a nephrotic syndrome for 17 months since the commencement of cyclic rituximab therapy aimed at suppression of pathogenetic gamma heavy chains. Free light chains in serum and CD20-positive cells in peripheral blood were useful as hematological markers in the patient. Rituximab might be a potent therapeutic option for AH amyloidosis associated with a B-cell lymphoproliferative disorder. |
| | |
Authors:
|
Nagaaki Katoh; Masayuki Matsuda; Daigo Miyazaki; Takahisa Gono; Masahide Yazaki; Shu-Ichi Ikeda |
Related Documents
:
|
3909583 - Five hundred years of the nephrotic syndrome: 1484-1984. 3050523 - Pathogenesis of sodium and water retention in high-output and low-output cardiac failur... 18774063 - Serotonin syndrome triggered by a single dose of suboxone. |
Publication Detail:
|
Type: Case Reports; Letter; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis Volume: 16 ISSN: 1744-2818 ISO Abbreviation: Amyloid Publication Date: 2009 |
Date Detail:
|
Created Date: 2010-06-11 Completed Date: 2010-09-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9433802 Medline TA: Amyloid Country: England |
Other Details:
|
Languages: eng Pagination: 178-80 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amyloidosis
/
complications*,
drug therapy*,
etiology Antibodies / genetics, immunology Antibodies, Monoclonal / therapeutic use* Antirheumatic Agents / therapeutic use* Female Humans Middle Aged Neoplasms, Plasma Cell / complications, drug therapy Nephrotic Syndrome* / drug therapy, etiology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies; 0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/rituximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-as...
Next Document: Compassion satisfaction, compassion fatigue, and burnout in a national sample of trauma treatment th...